Lymphedema Diagnostics Market Rising prevalence of Cancer and Lymphedema is Projected to Boost Market Growth at a CAGR of 7.50% During the Forecast Period of 2023 to 2030

Pune, India, February 2023, MRFR Press Release/- Market Research Future has published a Half-Cooked Research Report on the Global Lymphedema Diagnostics Market.

Global Lymphedema Diagnostics Market Highlights

According to MRFR analysis, the global lymphedema diagnostics market is expected to register a CAGR of ~7.50% during the forecast period of 2023 to 2032 and to reach USD 0.038 Billion by 2032.

Lymphatic obstruction or lymphedema is a long-term condition where the excess fluid forms in the body tissue and causes swelling commonly called edema. It develops due to the damaged lymphatic system. Sometimes it also develops after the treatment of breast cancer.

The growth of the global lymphedema diagnostics market is determined by numerous factors such as increasing incidence of cancer, high prevalence of lymphedema, and the adoption of new diagnostic modalities. However, the short half-life of radiopharmaceuticals and the high cost of diagnostic tests is projected to restrain the growth of the market during the forecast period.

The global lymphedema diagnostics market is currently dominated by several market players. The key players are involved in expansion, acquisition, and strategic collaborations to strengthen their market positions.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is anticipated to hold the largest market share owing to the high prevalence of lymphedema, well-established healthcare sector, and presence of the prominent players in this region. The lymphedema diagnostics market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.

The European lymphedema diagnostics market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The lymphedema diagnostics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the rising prevalence of cancer and the expansion of healthcare facilities, the market in Asia-Pacific is expected to be the fastest-growing. The lymphedema diagnostics market in the Middle East & Africa has been divided into the Middle East and Africa.

Explore In-depth Details: Lymphedema Diagnostics Market Research Report

Segmentation

The global lymphedema diagnostics market has been segmented based on type, technology, disease type, and end user.

The market, based on type, has been divided into primary and secondary. The secondary lymphedema is likely to hold maximum market share in the global lymphedema diagnostics market owing to the large population related to the secondary lymphedema presence across the globe.

The global lymphedema diagnostics market based on technology has been segregated into lymphoscintigraphy, magnetic resonance imaging, computed tomography, ultrasound imaging, and others. The lymphoscintigraphy segment is anticipated to hold the largest share in the market due to the large preference for the test.

The global lymphedema diagnostics market based on disease type has been segregated into cancer, inflammatory diseases, cardiovascular disease, and others. The cancer segment is anticipated to hold the largest share in the market as a cancer treatment is one of the major factors causing lymphedema.

The end-user segments of the market are hospitals, diagnostic centers, and others. The hospital's segment is expected to hold the largest share of the market, as these are the primary locations where patients receive diagnosis & treatment.

Key Players

Some of the key players in the global lymphedema diagnostics market are Siemens Healthineers, GE Healthcare, Stryker Corporation, Philips, Shimadzu Corporation, Canon, Inc., United Imaging Healthcare Co., Ltd., Hitachi, Ltd., Fluoptics, and Esaote SPA.